MAPK7 and cancer: Moreover, in MDA-MB-231 cells ERK5 inhibition by TG02 augmentedanti-cancer effects of chemotherapeutic agents conventionally used in TNBC treatment,including taxotere, vinorelbine, and cisplatin [22].